CD4+/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir and rilpivirine.

IF 3.4 2区医学 Q3 IMMUNOLOGY

AIDS Pub Date : 2024-11-01 Epub Date: 2024-09-26 DOI:10.1097/QAD.0000000000003984

Camilla Muccini, Nicola Gianotti, Riccardo Lolatto, Silvia Nozza, Sara Diotallevi, Antonella Castagna

引用次数: 0

Abstract

Our study assessed the CD4+/CD8+ ratio in people with HIV (PWH) switching from a second-generation integrase inhibitor regimen to long-acting cabotegravir (CAB) and rilpivirine (RPV). Over one year, we observed a significant improvement in the CD4+/CD8+ ratio; In addition, our data showed that time spent in CAB+RPV was significantly associated with an increased CD4+/CD8+ ratio. These findings suggest that long-acting therapy may enhance immune recovery, also in treatment-experienced PWH.

查看原文本刊更多论文

从第二代整合酶抑制剂方案转为长效卡博替拉韦和利匹韦林方案后，CD4+/CD8+有所改善。

我们的研究评估了从第二代整合酶抑制剂方案转为长效卡博特拉韦（CAB）和利匹韦林（RPV）方案的艾滋病病毒感染者（PWH）的 CD4+/CD8+ 比率。在一年的时间里，我们观察到 CD4+/CD8+ 比率有了明显改善；此外，我们的数据显示，接受 CAB+RPV 治疗的时间与 CD4+/CD8+ 比率的增加有显著关系。这些研究结果表明，长效疗法可以促进免疫功能的恢复，对有治疗经验的 PWH 也是如此。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

AIDS 医学-病毒学

CiteScore

5.90

自引率

5.30%

发文量

478

审稿时长

3 months

期刊介绍： Publishing the very latest ground breaking research on HIV and AIDS. Read by all the top clinicians and researchers, AIDS has the highest impact of all AIDS-related journals. With 18 issues per year, AIDS guarantees the authoritative presentation of significant advances. The Editors, themselves noted international experts who know the demands of your work, are committed to making AIDS the most distinguished and innovative journal in the field. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.